CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03422536
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:14.153132+00:00
Published At: 2023-07-19T00:00:00+00:00
Record Updated At: 2024-09-04
Results Posted At: 2023-07-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Head and Neck Basaloid Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Squamous Cell Carcinoma of Unknown Primary Origin", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IV Oropharyngeal Squamous Cell Carcinoma", "Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IVA Oropharyngeal Squamous Cell Carcinoma", "Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IVB Oropharyngeal Squamous Cell Carcinoma", "Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma", "Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma", "Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Stage IVC Oropharyngeal Squamous Cell Carcinoma", "Head and Neck Cancer", "Oropharyngeal Cancer", "HNSCC", "Stage IV Lip and Oral Cavity Squamous Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-09-04"
protocolSection.identificationModule.nctId: "NCT03422536"
protocolSection.identificationModule.officialTitle: "A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-07-19"

Study condition terms

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.